Ferdinando Riccardi

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo et al. · Journal of Clinical Oncology · 2012 · 232 citations · Full text

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

Marcello Tiseo, Luca Boni, Francesca Ambrosio et al. · Journal of Clinical Oncology · 2017 · 182 citations

Cancer Management, Pathology, Arm B +17

Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors

Francesco Panzuto, Maria Rinzivillo, Nicola Fazio et al. · The Oncologist · 2014 · 102 citations · Full text

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial

Francesco Perrone, Michelino De Laurentiis, Sabino De Placido et al. · European Journal of Cancer · 2019 · 68 citations

Ovarian Function Suppression, Oncology, Breast Oncology +13